How2Exit

OCTOBER 21, 2024

After a decade in corporate healthcare, he ventured into entrepreneurship, successfully growing and eventually exiting multiple businesses, including a medical billing company and a home health and hospice service. The discussion delves into Nicholas's investment philosophy and approach to building a diverse portfolio within his hold company.

Mergers and Acquisitions 130

Mergers and Acquisitions Acquisitions Healthcare Business 130

Software Equity Group

MARCH 26, 2024

Based in the Netherlands and with additional offices in Antwerp, Boston, Dusseldorf, and Stockholm, the firm maintains a diverse international portfolio of companies across the consumer products, consumer services, SaaS, information technology, healthcare, and ad tech sectors. The firm employs 93 professionals.

Private Equity 52

Private Equity Equities Investment Portfolio 52

How2Exit

MAY 9, 2023

Once the financials and legal aspects are understood, it is important to negotiate the terms of the purchase. Concept 2: DSOs and MSOs Buy Practices One of the topics discussed on the How to Exit podcast is the purchase of dental and medical practices by Dental Service Organizations (DSOs) and Medical Service Organizations (MSOs).

Business 130

Business Investment IT Economics 130

Focus Investment Banking

APRIL 1, 2024

All PPM organizations, including those in ENT & allergy, are designed to acquire, operate, and grow medical practices. Leveraging scale and knowing how to negotiate better rates with payors. Exits” – where private equity firms sell a PPM company from their portfolio – have also been very limited.

Private Equity 52

Private Equity Equities Negotiation Investment 52

Focus Investment Banking

MARCH 28, 2024

Exits” – where private equity firms sell a PPM company from their portfolio – have also been very limited. EyeSouth Partners, EyeCare Partners, Vision Innovation Partners) have already experienced recapitalizations and are young in their new sponsor’s portfolio. A third group (e.g., We also see them being aggressive about acquisitions.

Private Equity 52

Private Equity Equities Valuation Acquisitions 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 20, 2022

approved prescription cannabidiol medicine to its portfolio. In November, Johnson & Johnson announced that it will split itself into two publicly traded companies , separating its pharmaceutical and medical devices businesses from its consumer products business. driven assets. 19 fueled revenue aside, cash is still king.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40